A Phase III, Double-blind, Placebo-controlled Extension Trial to Investigate the Long-term Efficacy and Safety of Low (50 mg/Day) and High (100 mg/Day) Dose Safinamide, as add-on Therapy in Subjects With Early Idiopathic Parkinson's Disease Treated With a Stable Dose of a Single Dopamine Agonist [EXTENSION OF 700028966]
Latest Information Update: 23 Dec 2021
At a glance
- Drugs Safinamide (Primary)
- Indications Parkinson's disease
- Focus Registrational; Therapeutic Use
- Acronyms MOTION-extension
- Sponsors Merck Serono; Newron Pharmaceuticals
- 05 Oct 2021 This trial has been completed in Spain (End Date: 18 Jun 2012), according to European Clinical Trials Database record.
- 07 Mar 2013 New trial record